Actualités

Cigna Group has lagged the broader market despite consistent earnings performance, while analysts remain moderately optimistic about its future prospects.

The S&P 500 (^GSPC) is home to the biggest and most well-known companies in the market, making it a go-to index for investors seeking stability. But not all large-cap stocks are created equal - some are struggling with slowing growth, declining margins, or increased competition.

Cigna Group stock has delivered a 47.1% total return over the past 5 years, yet current valuation checks still lean toward the shares looking inexpensive rather than fully priced in. In light of recent earnings news and a steady long term track record, investors are weighing whether the recent price of US$282.49 already reflects this progress. Over 5 years, a 47.1% return suggests Cigna Group has rewarded patient shareholders while still inviting a closer look at whether the current price...

In the health insurance arena, one company is both the undisputed leader and the most expensive ticket, forcing investors to decide if paying up for quality is a winning strategy.

A mix of high expectations, profit-taking, and a slight dip in valuations has sent S&P 500 stocks sputtering even after solid earnings reports.

UnitedHealth's revenue held up; the operating margin on it did not, and closing that gap is the whole upside case.

Walmart downgraded, Palantir upgraded: Wall Street's top analyst calls

Investing.com -- Raymond James downgraded Cigna Group to Outperform from Strong Buy and lowered its price target to $320 from $350, saying the health insurer's valuation remains attractive but near-term catalysts are lacking as growth moderates and its pharmacy benefit management (PBM) business faces ongoing headwinds. The brokerage said Cigna operates in a mature market with slower growth than other names under its coverage and expects continued investments in the PBM transition, combined with

The lever behind UnitedHealth stock's climb was a Medicare Advantage repricing management had described months before the run began, and the hard part was believing a plan whose author had just been wrong.

The Cigna Group recently reported past second-quarter 2026 results showing higher sales of US$67.03 billion, revenue of US$71.67 billion, and net income of US$1.66 billion, alongside increased earnings per share from continuing operations versus a year earlier. Alongside raising its full-year adjusted earnings outlook, Cigna continued capital returns through share repurchases and affirmed a quarterly dividend of US$1.56 per share, while pressing ahead with its rebate-free Signature pharmacy...

Cigna Group (NYSE:CI) raised its full-year 2026 adjusted earnings outlook after reporting second-quarter results that management said exceeded expectations in both its Evernorth health services business and Cigna Healthcare insurance segment. The company reported second-quarter total revenue of $71

The telehealth company is making a bold pivot that's driving growth, but the stock's recent slide has investors wondering if the price of admission is still too high.

Adjusted EPS of $7.78 beats expectations, leading to a full-year outlook increase to at least $30.45, as Specialty and Care Services surge 22%.

The headline numbers for Cigna (CI) give insight into how the company performed in the quarter ended June 2026, but it may be worthwhile to compare some of its key metrics to Wall Street estimates and the year-ago actuals.

Cigna (CI) delivered earnings and revenue surprises of +2.64% and +0.18%, respectively, for the quarter ended June 2026. Do the numbers hold clues to what lies ahead for the stock?

Health insurance company Cigna (NYSE:CI) reported Q2 CY2026 results topping the market’s revenue expectations, with sales up 6.8% year on year to $71.67 billion. Its non-GAAP profit of $7.78 per share was 2.4% above analysts’ consensus estimates.

Cigna Group lifted its outlook and reported a higher profit in the second quarter, driven by growth in both its healthcare and pharmacy-benefit businesses.

Cigna Group will report its earnings on Thursday under its new chief executive, Brian Evanko. It’s transitioning its pharmacy benefits business to a rebate-free model.

CI's Q2 earnings are likely to face pressure from fewer insured medical customers and a higher MCR despite expected revenue growth.

Looking beyond Wall Street's top-and-bottom-line estimate forecasts for Cigna (CI), delve into some of its key metrics to gain a deeper insight into the company's potential performance for the quarter ended June 2026.

The healthcare giant looks expensive on today's numbers, but a patient investor is effectively buying it at a significant discount to that price.

A company that generates cash isn’t automatically a winner. Some businesses stockpile cash but fail to reinvest wisely, limiting their ability to expand.

Investors are rightly focused on the company's Medicaid struggles, but the real upside story may be hiding in plain sight across the rest of its business.

UnitedHealth's stock is flying high after it raised guidance, but on its latest earnings call, analysts zeroed in on an underlying margin divergence running right through the business.

The stock is trading near 52-week highs, but under the surface, commercial segment cost trends are creating headwinds.

The sticker price on CVS shares looks high, but the real question is what it costs on the earnings expected two years from now.

The health insurer raised its forecast after a solid quarter, but investors focused on the one business so broken it’s forcing a strategic retreat.

The stock is priced for strength, but a deep and persistent drag from one of its largest divisions could challenge the optimistic narrative.

The Federal Trade Commission announced a settlement with CVS Health’s pharmacy benefit manager business on Tuesday, the agency’s second major agreement this year with drug industry middlemen. Pharmacy-benefit managers, or PBMs, play a key role in negotiating with drug companies and selecting which prescription drugs will be covered by an insurance plan. In litigation filed in 2024 during the Biden administration, the commission alleged that rebates and fees collected by major PBMs from drug manufacturers artificially inflated the price of insulin.

Check out the companies making headlines yesterday: